- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
DC Needle Exchanges Curb Spread of HIV
Predictive modeling determined that the needle exchange in Washington, DC, prevented 120 new cases of HIV in 2 years, according to researchers.
Needle exchanges can prevent new cases of HIV, according to a new study published in AIDS and Behavior. After Washington, DC, lifted the ban on spending city money on needle exchanges, the researchers used a modeling technique to predict how many HIV infections would have occurred if the ban remained. They determined that the needle exchange prevented 120 new cases in 2 years.
Intravenous drug users can trade dirty syringes for clean ones at needle exchanges, which have been controversial programs to implement and spend city money on. While proponents claim needle exchanges curb the spread of HIV, opponents argue that the existence of these programs enable addicts to keep using.
In 1988, Congress banned the use of federal funds for needle exchanges. However, the District of Columbia was unable to use its own money until 2007, because Congress oversees its budget. The DC ban was lifted in late 2007 and the needle exchange program was implemented.
Read more at USA Today: http://usat.ly/1IN4e0B
Sociodemographic Factors Impact Cytoreductive Surgery Decisions in Advanced Ovarian Cancer
April 9th 2025Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in nonmetropolitan areas, and were unmarried had higher odds of refusing cytoreductive surgery.
Read More
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
Meta-Analysis Finds SGLT2 Inhibitors Boost Hemoglobin, Hematocrit in CKD
April 8th 2025The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for patients with chronic kidney disease (CKD) not only for their established benefits but also for addressing anemia.
Read More
